Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ALNA

Allena Pharmaceuticals (ALNA) Stock Price, News & Analysis

Allena Pharmaceuticals logo

About Allena Pharmaceuticals Stock (NASDAQ:ALNA)

Key Stats

Today's Range
N/A
50-Day Range
$0.02
$0.16
52-Week Range
N/A
Volume
96,558 shs
Average Volume
15.69 million shs
Market Capitalization
$37,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.

Receive ALNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allena Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ALNA Stock News Headlines

Allena Pharmaceuticals Inc ALNAQ Stock Quote
Allena Pharmaceuticals Inc (ALNAQ)
Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners
Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…
San Francisco Pharmaceuticals News
ALNA.O
See More Headlines

ALNA Stock Analysis - Frequently Asked Questions

Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) issued its earnings results on Thursday, March, 31st. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.06.

Allena Pharmaceuticals (ALNA) raised $80 million in an initial public offering (IPO) on Thursday, November 2nd 2017. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Allena Pharmaceuticals investors own include Predictive Oncology (POAI), Ford Motor (F), Bank of America (BAC), TherapeuticsMD (TXMD), Sorrento Therapeutics (SRNE), Zomedica (ZOM).

Company Calendar

Last Earnings
3/31/2022
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ALNA
Employees
35
Year Founded
N/A

Profitability

Net Income
$-48,660,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.23 per share

Miscellaneous

Free Float
117,566,000
Market Cap
$37,000.00
Optionable
Not Optionable
Beta
1.13
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:ALNA) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners